The advisory meeting was held in November, not January. https://www.biospace.com/article/fda-advisory-committee-rejects-biogen-s-alzheimer-s-treatment-/ The decision was scheduled for March, but moved to June based on Biogen providing more data. https://investors.biogen.com/news-releases/news-release-details/biogen-and-eisai-announce-fdas-3-month-extension-review-period Otherwise, thanks for your info, Doc. ANAVEX NOW ... RIGHT NOW ... MONO-STYLE ... for LIFE ... and for ALL AGES!!!
Market Data 
Markets
